The approval is based on results from the Phase III VIALE-A study as well as the Phase Ib M14-358 clinical trial The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie ...

Data from multiple studies have demonstrated the efficacy of Venclexta/Venclyxto in treating relapsed or refractory chronic lymphocytic leukemia, according to Roche. Data from multiple studies have ...

AbbVie’s Venclyxto is now available on the National Health Service in England via the Cancer Drugs Fund for patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL), on the ...

New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated ...

AbbVie has struck a deal with NICE to make its leukaemia drug Venclyxto available through the Cancer Drugs Fund. The new treatment Venclyxto (venetoclax) is to be available to NHS patients in England ...

The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who ...

"Results from the CLL14 and MURANO studies demonstrate the long-term benefits of fixed-duration venetoclax combinations for patients living with CLL," said Mariana Cota Stirner, M.D., Ph.D., vice ...

- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to ...

In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall ...

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for a kind of ...

VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, ...